Aclaris Therapeutics to Share Trial Results#
Aclaris Therapeutics, a biopharmaceutical company based in Wayne, Pennsylvania, is set to release the complete results from its Phase 1a trial of the bispecific antibody ATI-052 on Tuesday morning, before the stock market opens. This trial tested both single and multiple ascending doses of the drug, which targets specific proteins involved in inflammation.
Updates on ATI-2138#
In addition to the ATI-052 results, Aclaris will also provide updates on its lead indication selection process for another drug, ATI-2138, which is designed to inhibit certain pathways involved in immune responses. The company will host a conference call and webcast at 8:30 AM EST to discuss these developments, making it accessible for investors and interested parties.
Recent Performance and Financial Health#
Aclaris shares have experienced a significant increase of 221% over the past year, currently trading at $4.41, close to its 52-week high of $4.89. The company has a strong financial position, with more cash than debt, reflected in a current ratio of 3.36. This financial stability allows Aclaris to continue advancing its clinical programs effectively.
Future Developments#
The company is also making strides in other areas, having recently completed patient enrollment for a Phase 2 trial of bosakitug, aimed at treating moderate-to-severe atopic dermatitis. Results from this trial are expected in late 2026. Analysts have shown optimism regarding Aclaris, with ratings suggesting positive expectations for its future performance. The webcast discussing the trial results will be available on Aclaris's investor relations website for 30 days after the event.